Repligen Corporation to Present at Wells Fargo Healthcare Conference
Repligen (NASDAQ:RGEN), a leading bioprocessing technology company in the life sciences sector, has announced its participation in the upcoming Wells Fargo Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Repligen (NASDAQ:RGEN), a leading bioprocessing technology company in the life sciences sector, has announced its participation in the upcoming Wells Fargo Healthcare Conference. The event is scheduled to take place from September 4-6 in Boston.
Olivier Loeillot, Repligen's President and CEO, will engage in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET. Investors and interested parties can access a live webcast of the presentation through Repligen's Investor Relations website at www.repligen.com. The replay of the presentation will be available for a time after the event.
This conference provides Repligen with an opportunity to showcase its latest developments and strategic initiatives in the bioprocessing technology field to investors and industry analysts.
Details
News Market Reaction – RGEN
The recorded move for RGEN in the trading session of this news was -0.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 4-6 in Boston. Olivier Loeillot, President and Chief Executive Officer will participate in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET.
A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.